Otsuka, Lundbeck Sue Viatris Again on Abilify Maintena Copy (1)

Otsuka Holdings Co. and H. Lundbeck AS expanded their legal fight over Viatris Inc.’s proposed generic version of Abilify Maintena, alleging in Delaware federal court that it infringes a patent issued May 31 for the monthly injectable treatment for schizophrenia that Lundbeck exclusively licenses from Otsuka.

Otsuka and Lundbeck filed the complaint against Viatris, formerly known as Mylan, Aug. 26 in the US District Court for the District of Delaware. It follows two April lawsuits involving the same parties that were filed in Delaware and the Northern District of West Virginia over eight other patents for the drug. The ...